Filing Details

Accession Number:
0001179110-16-024699
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-05-16 08:25:42
Reporting Period:
2016-05-12
Filing Date:
2016-05-16
Accepted Time:
2016-05-16 08:25:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1544227 Ovascience Inc. OVAS Pharmaceutical Preparations (2834) 451472564
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1551614 Michelle Dipp C/O Ovascience, Inc.
9 Fourth Ave.
Waltham MA 02451
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-05-12 14,200 $6.72 455,161 No 4 P Indirect By Longwood Fund III LP
Common Stock Acquisiton 2016-05-12 5,600 $7.13 460,761 No 4 P Indirect By Longwood Fund III LP
Common Stock Acquisiton 2016-05-13 16,295 $7.06 477,056 No 4 P Indirect By Longwood Fund III LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Longwood Fund III LP
No 4 P Indirect By Longwood Fund III LP
No 4 P Indirect By Longwood Fund III LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 971,921 Direct
Footnotes
  1. This Form 4 reflects the purchase of an aggregate of 36,095 shares by the Longwood Fund III LP in the market. The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D. and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.99, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.00 to $7.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.62 to $7.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.